Friedlaender, A. . (2020) “Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab”, Acta Oncologica, 59(9), pp. 1058–1063. doi: 10.1080/0284186X.2020.1781249.